21 August 2025
ECO Animal Health Group plc
("ECO" or the "Company")
Result of General Meeting
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that at a General Meeting held earlier today, the single special resolution proposed was duly passed.
As a result, trustees of the ECO Animal Health Group Employee Benefit Trust will shortly commence limited on-market purchases of the Company's ordinary shares of 5 pence each.
Voting results from the General Meeting will be made available on the Company's website at https://ecoanimalhealth.com/investors/.
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer) |
|
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson |
020 3709 5700 |
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Sam Butcher |
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Lydia Zychowska |
020 7597 5970 |
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com